Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

by Zacks Equity Research

Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.

Kinjel Shah headshot

Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others

by Kinjel Shah

Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.

Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe

by Zacks Equity Research

The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.

Allergan (AGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Allergan (AGN) closed the most recent trading day at $164, moving +1% from the previous trading session.

The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers

Sweta Jaiswal, FRM headshot

ETFs Poised to Benefit from Gene Editing Revolution

by Sweta Jaiswal, FRM

Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

Kinjel Shah headshot

Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs

by Kinjel Shah

Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.

Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease

by Zacks Equity Research

Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.

Allergan (AGN) Up 1.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allergan (AGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Allergan (AGN) closed the most recent trading day at $161.69, moving +1.18% from the previous trading session.

Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study

by Zacks Equity Research

Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.

Allergan Settles Ahead of Multi-District Opioid Litigation

by Zacks Equity Research

Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.

Indrajit Bandyopadhyay headshot

Will Opioid Litigation Take its Toll on Pharma Companies?

by Indrajit Bandyopadhyay

Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.

J&J Up Despite $572M Fine in Oklahoma Opioid Abuse Case

by Zacks Equity Research

A court ordered J&J (JNJ) to pay $527 million in the Oklahoma litigation related to abuse of its opioid-based drugs. The company is facing similar litigation in multiple states.

Amgen Presents Positive Data From Rituxan Biosimilar Study

by Zacks Equity Research

Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.

J&J's (JNJ) Opioid Lawsuit Verdict in Oklahoma Due Next Week

by Zacks Equity Research

J&J (JNJ) is facing several litigation in multiple states related to abuse of its opioid-based drugs. A ruling is expected on Aug 26 in a trial filed by the state of Oklahoma.

Endo Up on Settlement of a Few Cases Related to Opioid Drugs

by Zacks Equity Research

Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications.

Here's Why Allergan is Outperforming Its Industry Of Late

by Zacks Equity Research

Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.

Implied Volatility Surging for Allergan (AGN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Allergan (AGN) stock based on the movements in the options market lately.

Here's Why Amgen Stock is Outperforming Its Industry Of Late

by Zacks Equity Research

Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.

Can Value Investors Consider Allergan (AGN) a Worthy Pick?

by Zacks Equity Research

Allergan (AGN) stock may be a good choice for value-oriented investors right now from multiple angles.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients

by Kinjel Shah

Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.

Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down

by Zacks Equity Research

Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.

Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO

by Zacks Equity Research

In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.

Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

by Zacks Equity Research

Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.